Shanghai Rightongene Biotechnology Co Ltd
SSE:688217
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
S
|
Shanghai Rightongene Biotechnology Co Ltd
SSE:688217
|
1.7B CNY |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
383.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
201.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
181.6B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Shanghai Rightongene Biotechnology Co Ltd
Glance View
Shanghai Rightongene Biotechnology Co., Ltd. engages in the research and development, production, and sale of in vitro diagnostic products. The company is headquartered in Shanghai, Shanghai and currently employs 503 full-time employees. The company went IPO on 2021-05-17. The firm's main products include leukemia molecular diagnostic kits and lymphoma molecular diagnostic kits. The firm mainly provides precise gene and antigen testing services for patients with blood diseases, solid tumors and infectious diseases. The firm also provides scientific research services applied in basic research, disease typing, drug adaptability and target genetic testing. The firm mainly conducts its businesses within domestic market.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Shanghai Rightongene Biotechnology Co Ltd is -18.7%, which is below its 3-year median of -5.2%.
Over the last 3 years, Shanghai Rightongene Biotechnology Co Ltd’s Operating Margin has decreased from 10.7% to -18.7%. During this period, it reached a low of -18.7% on Jul 30, 2025 and a high of 18% on Dec 31, 2022.
